Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 12 versus VARIBAR THIN LIQUID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 12 versus VARIBAR THIN LIQUID.
OMNIPAQUE 12 vs VARIBAR THIN LIQUID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
VARIBAR THIN LIQUID (barium sulfate) is a radiopaque contrast agent. Its mechanism involves coating the mucosal surface of the gastrointestinal tract, attenuating X-rays, and providing radiographic visualization of anatomical structures.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
Oral administration: 30-100 mL of a 30% w/v barium sulfate suspension, given as a single dose for upper GI studies; adjust volume and concentration based on imaging technique and patient anatomy.
None Documented
None Documented
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Not applicable; the compound is not absorbed and does not exhibit a systemic half-life. Gastrointestinal transit time is approximately 1-3 hours for small bowel follow-through, with colonic elimination occurring over 24-72 hours.
Renal: >95% unchanged; biliary/fecal: <5%
VARIBAR THIN LIQUID (barium sulfate) is not absorbed systemically. It is eliminated entirely via the gastrointestinal tract, with >99% excreted unchanged in feces within 24-72 hours. Renal or biliary elimination is negligible (<0.01%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent